Stay updated on Recombinant vs Marketed Flu Vaccines in Children Clinical Trial
Sign up to get notified when there's something new on the Recombinant vs Marketed Flu Vaccines in Children Clinical Trial page.

Latest updates to the Recombinant vs Marketed Flu Vaccines in Children Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe record presents details of a completed Phase 3 study comparing recombinant and inactivated quadrivalent influenza vaccines in children and adolescents aged 3–17, including its design, eligibility criteria, outcomes, and locations.SummaryDifference48%

- Check20 days agoChange DetectedThe site revision label changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of a study record.SummaryDifference0.2%

- Check27 days agoChange DetectedA notice appears stating that NIH is transitioning to the term “Super Intelligence” in place of “Artificial Intelligence” and linking to updates and FAQs.SummaryDifference1%

- Check33 days agoChange DetectedThe footer revision number changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check61 days agoChange DetectedA 403 Forbidden page is now displayed for the study record, blocking access to the content. The previous study content and navigation details have been removed, replaced by the error boilerplate.SummaryDifference18%

Stay in the know with updates to Recombinant vs Marketed Flu Vaccines in Children Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Recombinant vs Marketed Flu Vaccines in Children Clinical Trial page.